None
Quote | Replimune Group Inc. (NASDAQ:REPL)
Last: | $6.315 |
---|---|
Change Percent: | -1.64% |
Open: | $6.41 |
Close: | $6.42 |
High: | $6.66 |
Low: | $6.2 |
Volume: | 146,760 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Replimune Group Inc. (NASDAQ:REPL)
2024-04-24 04:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 06:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Replimune Group Inc. (NASDAQ:REPL)
Subject | By | Source | When |
---|---|---|---|
ASCO Initial efficacy and safety of RP1 + nivolumab | jondoeuk | investorshub | 04/30/2023 5:31:31 PM |
It made headlines both sides of the pond. | jondoeuk | investorshub | 04/13/2023 10:58:14 PM |
(OT) Identification of a viral 5'leader that augments | jondoeuk | investorshub | 04/07/2023 12:02:26 AM |
More here https://www.evaluate.com/vantage/articles/news/trial-results/replimune | jondoeuk | investorshub | 03/19/2023 10:32:34 PM |
Link to webcast https://www.wsw.com/webcast/cc/repl3/register.aspx?conf=cc&page= | jondoeuk | investorshub | 12/06/2022 1:09:05 AM |
News, Short Squeeze, Breakout and More Instantly...
Replimune Group Inc. Company Name:
REPL Stock Symbol:
NASDAQ Market:
2024-04-24 04:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 06:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial eva...